Graybug Vision is a clinical stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic vision-threatening diseases of the retina and optic nerve.
Our proprietary ocular delivery technologies, which are designed to maintain potent and effective drug levels in ocular tissue for up to 12 months and potentially longer, will improve patient compliance, reduce healthcare burdens and ultimately improve clinical outcomes.
Graybug Vision’s initial technology was co-developed by founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with co-founders and leading ophthalmology clinician-scientists from the Wilmer Eye Institute, Peter A. Campochiaro, MD and Peter J. McDonnell, MD. The company was founded in September 2011 as a spin-out of the world-renowned Wilmer Eye Institute of the Johns Hopkins University School of Medicine.
We are developing our lead product candidate, GB-102, an inhibitor of multiple neovascular pathways, for the intravitreal, or IVT, treatment of retinal diseases, including wet age-related macular degeneration, or wet AMD, with a six-month dosing regimen. Our approach is differentiated from the current standard of care, which requires more frequent dosing, often monthly or bi-monthly, and only targets one pathway. Wet AMD affects approximately two million adults in the United States and is a leading cause of vision loss.
We are developing GB-401 for the reduction of elevated intraocular pressure, or IOP, in patients with primary open angle glaucoma, or POAG. We designed GB-401 with the goal of improving glaucoma patient outcomes through increased compliance and a favorable tolerability and safety profile. More than three million Americans are living with glaucoma, a leading cause of blindness, with POAG being the most common form.